Evidence Hub

Tofacitinib for the Management of Coexisting Pemphigoid Nodularis and Psoriasis: A Case Report and Review of the Literature

Peng Qu, Na Wang, Bao-Qi Yang

Case Reports in Dermatology, 2025

1 citation

Abstract

Abstract Introduction: Pemphigoid nodularis is identified as a rare clinical variant of bullous pemphigoid (BP), often requiring detailed diagnostic methods due to its atypical presentations, with the concurrent occurrence of psoriasis being rare. Case Presentation: We report the use of tofacitinib in a 66-year-old female with pemphigoid nodularis combined with psoriasis with significant results. Conclusion: Our research suggests that tofacitinib could effectively treat pemphigoid nodularis in the presence of psoriasis, offering convenient administration and promising efficacy compared to traditional therapies.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free